血清sICAM-1在肝细胞肝癌患者TAE术后的动态变化及其意义

Change and significance of soluble intercellular adhesion molecule-1 in hepatocellular carcinoma patients after transcatheter arterial embolization

目的:检测肝细胞肝癌(hepaticcellcarcinoma,HCC)患者经动脉导管栓塞术(transcatheterarterialembolization,TAE)后血清sICAM-1的动态变化,以了解其在判断HCC经TAE治疗后疗效及判断再次TAE指征方面的意义。方法:运用ELISA方法测定12例HCC患者第1次TAE前、术后3、10、30d以及第2次TAE术后血清sICAM-1的水平,并对比第1次术前和术后10d肿块大小与血清sICAM-1的关系。结果:TAE术前HCC患者血清sICAM-1水平(973.00±211.54)明显高于对照组(P<0.01)。TAE术后3d显著下降(611.67±145.02)(P<0.01),术后30d有所回升(811.13±133.18),但仍低于术前(P<0.05)。再次TAE后3d下降(568.43±106.28)(P<0.01)。第1次TAE术后10d肿块缩小程度跟相应的sICAM-1下降幅度成正比,线性回归分析r=0.88(P<0.05)。结论:血清sICAM-1对判断HCCTAE后再次TAE的指征及评价TAE效果方面有一定的价值。

Objective To observe the changes of serum soluble intercellular adhesion molecule-1 （sICAM-1） in hepatocellular carcinoma （HCC） patients after transcatheter arterial embolization （TAE） and to identify clinical significance of serum sICAM-1 in estimating their prognosis and the indication of re-TAE treatment. Method Serum sICAM-1 in 12 HCC patients was measured by means of ELISA when before the first TAE, 3, 10, 30 days after TAE and 3 days after the second TAE, respectively, Results Compared with control group, the level of serum sICAM-1 in HCC patients before the first TAE（973.00 ± 211.54）was significantly increased, and then declined markedly 3, 10 and 30 days after the first TAE and 3 days after the second TAE （611.67 ± 145.02, 658.85 ± 156.47, 811.13 ± 133.18 and 568.43 ± 106. 28, P 〈 0. 01, P 〈 0.01, P 〈 0. 05 and P 〈 0. 01, respectively） . The diminished extent of tumor was directly correlated with the corresponding descent of serum sICAM-1 （ r = 0. 88, P 〈 0. 05） 10 days after the first TAE. Conclusion It is suggested that there is positive significance of dynamic changes of serum sICAM-1 in estimating the prognosis after TAE treatment and the indication of re-TAE treatment in HCC patinets.